253 related articles for article (PubMed ID: 20458210)
1. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
Astsaturov IA; Meropol NJ; Alpaugh RK; Burtness BA; Cheng JD; McLaughlin S; Rogatko A; Xu Z; Watson JC; Weiner LM; Cohen SJ
Am J Clin Oncol; 2011 Feb; 34(1):70-5. PubMed ID: 20458210
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
Kindler HL; Friberg G; Singh DA; Locker G; Nattam S; Kozloff M; Taber DA; Karrison T; Dachman A; Stadler WM; Vokes EE
J Clin Oncol; 2005 Nov; 23(31):8033-40. PubMed ID: 16258101
[TBL] [Abstract][Full Text] [Related]
3. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
[TBL] [Abstract][Full Text] [Related]
4. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
Wolpin BM; O'Reilly EM; Ko YJ; Blaszkowsky LS; Rarick M; Rocha-Lima CM; Ritch P; Chan E; Spratlin J; Macarulla T; McWhirter E; Pezet D; Lichinitser M; Roman L; Hartford A; Morrison K; Jackson L; Vincent M; Reyno L; Hidalgo M
Ann Oncol; 2013 Jul; 24(7):1792-1801. PubMed ID: 23448807
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
[TBL] [Abstract][Full Text] [Related]
7. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
El-Rayes BF; Zalupski M; Bekai-Saab T; Heilbrun LK; Hammad N; Patel B; Urba S; Shields AF; Vaishampayan U; Dawson S; Almhanna K; Smith D; Philip PA
Ann Oncol; 2010 Oct; 21(10):1999-2004. PubMed ID: 20332133
[TBL] [Abstract][Full Text] [Related]
10. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Ko AH; Dito E; Schillinger B; Venook AP; Xu Z; Bergsland EK; Wong D; Scott J; Hwang J; Tempero MA
Invest New Drugs; 2008 Oct; 26(5):463-71. PubMed ID: 18379729
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
Javle M; Yu J; Garrett C; Pande A; Kuvshinoff B; Litwin A; Phelan J; Gibbs J; Iyer R
Br J Cancer; 2009 Jun; 100(12):1842-5. PubMed ID: 19491904
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; An C; Park MS; Jung SY; Bang S
Semin Oncol; 2017 Dec; 44(6):420-427. PubMed ID: 29935903
[TBL] [Abstract][Full Text] [Related]
13. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
14. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
[TBL] [Abstract][Full Text] [Related]
15. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Borson R; Harker G; Reeves J; Beck T; Hager S; Horvath W; Jones M; Tillinghast G; Arrowsmith E; Harrer G; Kudrik FJ; Malamud SC; Bromund J; Zeigler H; Tai DF; Kornberg LJ; Obasaju C; Orlando M; Yardley DA
Clin Breast Cancer; 2012 Oct; 12(5):322-30. PubMed ID: 23040000
[TBL] [Abstract][Full Text] [Related]
17. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
18. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
Fortune BE; Li X; Kosuri KV; Weatherby LM; Thomas JP; Bekaii-Saab TS
Oncology; 2009; 76(5):333-7. PubMed ID: 19307739
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]